The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s protein inhibitors market report forecasts the protein inhibitors market size to grow to $105.43 Billion by 2027, with a CAGR (compound annual growth rate) of more than 9%.

Learn More On The Protein Inhibitors Market Report 2023 – https://www.thebusinessresearchcompany.com/report/protein-inhibitor-global-market-report

Protein Inhibitors Market Size Forecast
The global protein inhibitors market is expected to grow from $68.17 billion in 2022 to $74.3 billion in 2023 at a compound annual growth rate (CAGR) of 9.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The protein inhibitors market is expected to grow from $105.43 billion in 2027 at a CAGR of 9.1%.

North America held the largest protein inhibitors market share.

Key Protein Inhibitors Market Driver ­– Increase In The Prevalence Of Chronic Diseases
For instance, in May 2022, according to the World Health Organization, chronic diseases are expected to become the seventh leading cause of death globally by the end of 2030.In the USA, the number reached 157 million in 2020, with 87 million people having multiple conditions. Protein inhibitors are used for the treatment of these diseases attributing to fewer adverse effects and higher efficacy. Therefore, an increasing number of people with chronic diseases are anticipated to propel the demand for protein inhibitors market.

Request for A Sample Of The Global Protein Inhibitors Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3429&type=smp

Key Protein Inhibitors Market Trend – Developing New Drugs
Companies in the protein inhibitors market are increasingly investing in various strategic initiatives such as partnerships and collaborations to develop new drugs to meet the market demand. Strategic collaborations and partnership agreements help companies to expand their existing product portfolio and geographical presence. For instance, in February 2020, Catalent, Inc., a USA-based provider of delivery technologies, drug manufacturing, gene therapies, biologics, and consumer healthcare products announced a partnership agreement with Zumutor Biologics Inc., an immune-oncology company based in the USA to manufacture ZM008, a monoclonal antibody targeting solid tumors. Moreover, in February 2021, Eli Lilly and Company, a USA-based pharmaceutical company, and Rigel Pharmaceuticals, Inc., a USA-based biotechnology company, announced a global exclusive license agreement and strategic collaboration to co-develop and commercialize Rigel’s R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications, including autoimmune and inflammatory diseases.

Protein Inhibitors Market Segment
1) By Product: Protein Kinase Inhibitors, Monoclonal Antibody, Other Products
2) By Application: Oncology, Inflamatory Diseases, Other Applications
3) By Distribution Channel: Hospital Pharmacies, Independent Pharmacies, Online Pharmacies

Protein Inhibitors Market Major Players and Strategies
Major players in the protein inhibitors market are Bayer AG, Astra Zeneca, Roche, Teva, Apotex, Novartis, GlaxoSmithKline, Pfizer, Boehringer Ingelheim, and F. Hoffmann-La Roche.

In June 2022, Pfizer Inc., a US-based pharmaceutical and biotechnology company, acquired ReViral for $525 million. The acquisition strengthens Pfizer’s commitment to creating both medications and vaccines to help fight the respiratory syncytial virus while also expanding its anti-infective portfolio (RSV). ReViral is a UK-based clinical-stage biopharmaceutical company pioneering in the discovery and development of innovative antiviral drugs for disorders brought on by the respiratory syncytial virus.

The Protein Inhibitors Global Market Report 2023 covers regional data on protein inhibitors market size, protein inhibitors market trends and drivers, opportunities, strategies, and protein inhibitors market competitor analysis. The countries covered in the protein inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Protein inhibitors refer to compounds that interfere with the steps directly involved in the production of new proteins in cells. Protein inhibitors operate at the ribosome level, benefiting from the significant variations between prokaryotic and eukaryotic ribosome architectures.

View More Reports Related To The Protein Inhibitors Market –
Protein Expression Global Market Report 2023
Protein Labeling Global Market Report 2023
Vascular Endothelial Growth Factor (VEGF) Inhibitor Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: